Topic Hub
25 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Explore
Showing 25 of 25 clinical reviews.
A clinician-level review of pioglitazone use after bariatric surgery, covering pharmacokinetics, NASH evidence, insulin resistance, dosing, and safety in post-bariatric patients with type 2 diabetes or MASLD.
Read clinical reviewA clinician-reviewed deep dive into how pioglitazone (Actos) affects appetite, food cravings, and caloric intake, with primary-literature citations, dosing context, and practical monitoring guidance.
Read clinical reviewA physician-level review of pioglitazone use in patients with autoimmune conditions, covering PPAR-gamma immunomodulation, disease-specific risks, NASH evidence from PIVENS, and practical prescribing guidance.
Read clinical reviewA clinician-level review of how pioglitazone affects bone mineral density, fracture risk, and what monitoring steps reduce harm in patients with type 2 diabetes or NASH.
Read clinical reviewA comprehensive, physician-reviewed analysis of the bladder cancer, liver cancer, and other malignancy signals associated with pioglitazone (Actos), including trial data, FDA warnings, mechanistic hypotheses, and clinical decision guidance.
Read clinical reviewA physician-level review of pioglitazone's long-term cardiovascular effects, covering the PROactive trial, IRIS stroke data, heart failure risk, bladder cancer signals, and current ADA/AACE prescribing guidance.
Read clinical reviewA physician-reviewed deep dive into how pioglitazone affects cognitive function, covering PPAR-gamma mechanisms, clinical trial data, dementia-risk studies, and practical prescribing guidance for patients with type 2 diabetes.
Read clinical reviewA physician-reviewed comparison of compounded pioglitazone versus branded Actos, covering bioequivalence, safety, cost, off-label NASH use, and how to choose the right formulation for your patient.
Read clinical reviewA GRADE-rated review of pioglitazone's clinical evidence across type 2 diabetes, NASH/NAFLD, cardiovascular outcomes, and off-label uses. Covers landmark trials, guideline positions, safety signals, and practical prescribing thresholds.
Read clinical reviewA thorough clinical review of pioglitazone (Actos) effects on hair and skin, including edema, alopecia, PCOS-related improvements, and NASH-related skin findings, with primary-literature citations and dosing context.
Read clinical reviewA physician-level review of how pioglitazone affects liver function, AST/ALT dynamics, NASH resolution data from PIVENS, and monitoring protocols for safe clinical use.
Read clinical reviewA physician-reviewed deep dive into how pioglitazone (Actos) affects mood, depression, anxiety, and cognition in patients with type 2 diabetes and NASH, with primary-literature citations throughout.
Read clinical reviewA clinician-level review of how pioglitazone (Actos) alters glucose metabolism, fat oxidation, mitochondrial function, and energy expenditure in type 2 diabetes and NASH, with primary-literature citations throughout.
Read clinical reviewA physician-reviewed deep dive into pioglitazone microdosing protocols, low-dose evidence, NASH data from PIVENS, cardiovascular signals, and how clinicians are applying sub-standard doses off-label in 2024.
Read clinical reviewA clinician-level guide to preserving muscle mass in patients taking pioglitazone (Actos) for type 2 diabetes or NASH, covering mechanisms, resistance training, protein dosing, and monitoring protocols.
Read clinical reviewMD/PharmD-level guide to diagnosing and managing pioglitazone plateau and non-response: dose optimization, adherence checks, pharmacogenomics, combination strategies, and when to switch agents.
Read clinical reviewHow long before surgery should pioglitazone (Actos) be stopped? Board-reviewed guidance on the pre-surgery hold window, fluid-retention risks, anesthetic interactions, and restart protocols.
Read clinical reviewStopping pioglitazone (Actos) can trigger glycemic rebound, fluid shifts, NASH relapse, and cardiovascular changes. This MD-level guide covers the mechanisms, timelines, monitoring protocols, and tapering strategies backed by primary literature.
Read clinical reviewDoes pioglitazone protect the kidneys or harm them? This MD/PharmD-level review covers the clinical trial data, mechanisms, contraindications, and prescribing guidance for pioglitazone's renal effects in type 2 diabetes and NASH.
Read clinical reviewA clinician-level guide to how seasonal changes in temperature, diet, physical activity, and illness affect pioglitazone dosing, fluid retention, and glycemic control in type 2 diabetes and NASH.
Read clinical reviewA clinician-level review of how pioglitazone affects sexual function in men and women with type 2 diabetes, covering mechanisms, trial data, and clinical guidance.
Read clinical reviewA clinician-level review of how pioglitazone affects sleep architecture, REM sleep, sleep-disordered breathing, and overnight glucose regulation, with primary-literature citations and dosing guidance.
Read clinical reviewMD/PharmD-level guidance on traveling with pioglitazone: timezone dose-timing adjustments, flight hypoglycemia risk, storage requirements, customs documentation, and cross-border pharmacy access.
Read clinical reviewA physician-level guide to safely restarting pioglitazone after acute illness, covering hold criteria, timing, dose titration, monitoring, and the clinical evidence behind each recommendation.
Read clinical reviewA physician-reviewed, week-by-week guide to pioglitazone's first 30 days: when blood sugar drops, why fluid retention peaks in week 2, and what lab changes to track through day 28.
Read clinical review